Clinical trials located in

Badajoz

Badajoz city is located in Spain. Currently, 20 clinical trials are being conducted in this city.

Badajoz, located in western Spain near the Portuguese border, is the capital of the province of Badajoz in the autonomous community of Extremadura. Founded in pre-Roman times, it has a rich history evident in its well-preserved Alcazaba, a Moorish fortress dating back to the 9th century. The city played a significant role during the Peninsular War and has numerous historical sites, including the Plaza Alta and the Badajoz Cathedral. Its strategic location has made it a melting pot of cultures throughout the centuries.

  • CT-EU-00116971

    NCT05091346

    This here clinical trial is aimin’ to test out a new combination of drugs for treatin’ some tough cancers. The main drugs bein’ studied are E7386, a newfangled tablet, and pembrolizumab, which is given through an IV drip. For folks with liver cancer, they might also get lenvatinib capsules added to the mix.

    The first part of the trial is focused on findin’ the right doses of E7386 to use with pembrolizumab, makin’ sure the combination is safe and tolerable for patients. The doc’s will be keepin’ a close eye on any serious side effects durin’ this phase.

    If the doses look good, the second part will test how well this drug combo actually works against melanoma (skin cancer), colorectal cancer (cancer of the colon or rectum), and hepatocellular carcinoma (liver cancer). The main thing they’ll be measurin’ is the objective response rate, which means how many folks see their tumors shrinkin’ or disappearin’ altogether with this treatment.

    So in a nutshell, this trial is aimin’ to find a new, effective way to fight some of the toughest cancers out there usin’ a novel combination of medicines. If you’re interested in joinin’, be sure to ask your doctor about all the risks and benefits involved.

    SpainUnited Kingdom
  • Easing Neck Pain for Elderly-Care Workers: A 5-Week Physiotherapy Study

    Are you a healthcare worker dealing with non-specific neck pain? We’re conducting a study titled “Workplace Based Physiotherapy of Elderly-care Workers With Non-specific Neck Pain” that might interest you. This research aims to explore the effectiveness of a specialized physical therapy program tailored for individuals like you. The program includes manual therapy, therapeutic exercise, and electrotherapy to address neck pain issues.

    The study will last for five weeks, with a follow-up after one month to assess the long-term benefits. As a participant, you’ll undergo a series of 10 physiotherapy sessions, scheduled twice a week, designed to alleviate your neck pain. Our trained researchers will evaluate your condition before and after the intervention to measure the impact of the therapy.

    We’ll be looking at several key outcomes to determine the success of the treatment. The first is changes in pain, which we’ll assess using a visual analog scale. This scale helps us understand the intensity of your pain, ranging from no pain to unbearable pain. Secondly, we’ll measure changes in pressure pain through a technique called Algometry, focusing on the sensitivity of trigger points in your neck. Lastly, we’ll evaluate changes in disability using the Neck Disability Index, which considers both subjective symptoms and your ability to perform daily activities.

    If you’re experiencing neck pain and are interested in a potential solution, this study could be a great opportunity. Your participation will not only help you manage your pain but also contribute valuable data to improve care for healthcare workers with similar conditions.

    Spain
  • Testing new immunotherapy combinations for non-small-cell lung cancer

    This study is testing a new treatment for non-small cell lung cancer that has not yet been treated with drugs. In the study, researchers will look at the effects of combining different immunotherapy drugs and their safety and effectiveness in treating cancer. Participants will receive various combinations of the drugs pembrolizumab, dostarlimab, belrestotug and GSK6097608. The study will last several years and will monitor the effects of different drug combinations and any potential side effects. The study aims to find new ways to treat lung cancer with fewer negative side effects.

    BelgiumFinlandFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Study on new immunotherapy combinations for untreated advanced lung cancer

    This is a study of patients whose non-small cell lung cancer is at an advanced stage (cannot be cured by surgery or has spread to other parts of the body) and has not been previously treated. The study will test new combinations of immunotherapy (drugs that support the immune system in the fight against cancer) and compare them with a single immunotherapy drug. Scientists want to find out how well these combinations work and how safe they are. The study will also look at how the body processes these drugs. The drugs used in this study are called Belrestoug, GSK4428859A and EOS884448, but these names all refer to the same drug. Scientists will measure the effectiveness of the drugs by looking at how many patients have their cancer shrink and how long it takes for the cancer to start growing again or before the patient dies. They will also record any side effects that may occur during the study and for 90 days after the last treatment dose.

    BelgiumFinlandFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Study on trastuzumab deruxtecan for resistant breast cancer patients

    This clinical trial, also known as the TRANSCENDER trial, is investigating the effects of a drug called Trastuzumab Deruxtecan (T-DXd) in treating a specific type of advanced breast cancer called HER2-positive. This medicine is expected to work well in people whose disease has not responded or has had an early relapse following standard treatment. The aim is to find out how effectively this drug can slow down or possibly stop the growth of cancer cells, and how safe its use is for patients. Patients in this study will receive T-DXd intravenously every 3 weeks. The dose may be adjusted if the patient’s weight changes significantly. Treatment will continue until the cancer gets worse, side effects become too severe, or the patient decides to leave the study.

    Spain
  • Understanding the effects of tominersen on early-stage Huntington’s Disease

    This clinical trial focuses on evaluating the investigational drug, tominersen, in people in the early stages of Huntington’s disease-a genetic disorder characterised by the progressive breakdown of nerve cells in the brain. This study aims to understand the potential of tominersen to slow the progression of the disease and improve quality of life by administering different doses or placebo directly into the spinal cord to target the areas of the brain most affected by the disease. Participants’ health status will be rigorously monitored and a series of assessments will be conducted to track changes in motor function, cognitive abilities and emotional wellbeing. Additionally, the study will measure specific biomarkers to assess the biological impact of treatment, offering valuable information for tailoring future therapies. This study represents an important opportunity to better understand Huntington’s disease and explore effective treatment options.

    AustriaDenmarkFranceGermanyItalyPolandPortugalSpainUnited Kingdom
  • Study on new medicine and immune drugs for hard-to-treat tumors

    The safety and efficacy of a new drug, Zanzalintinib (XL092) is currently evaluated in investigation in a trial designed for individuals with inoperable solid tumors or those that have metastasized. The drug may be administered as a standalone treatment or in combination with other medications designed to stimulate the immune system’s response to combat cancer. The initial phase focuses on determining the appropriate dosage for Zanzalintinib. Subsequently, the trial aims to assess the effectiveness of Zanzalintinib and companion drugs in reducing tumor size and enhancing survival rates. Throughout the study, potential adverse reactions to the drug will also be monitored. During the second stage, the evaluation of Zanzalintinib will be expanded to analyze outcomes in patients with specific cancer types. The objective is to investigate whether the drug leads to a slower progression of cancer and a reduction in tumor size for individuals with these particular types of cancer.

    AustriaBelgiumFranceGermanyItalyPolandSpainUnited Kingdom
  • Study of alpelisib and fulvestrant for advanced breast cancer treatment

    This trial is looking at the effects of the combined use of two drugs, alpelisib and fulvestrant, in treating patients who have advanced breast cancer. The cancer should be HR-positive and HER2-negative, and have a specific mutation (PIK3CA). If the patients already underwent certain other treatments like CDK4/6 Inhibitors and aromatase Inhibitors, but the cancer has progressed, they could join this trial. Doctors will be able to compare the results of patients taking alpelisib and fulvestrant together, with those taking fulvestrant with a placebo, They aim to check which combination works better in delaying the advance of cancer or in improving a patient’s life duration.

    BelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyPolandPortugalRomaniaSlovakiaSpain
  • Inupadenant study in second-line non-small cell lung cancer

    This clinical trial aims to explore the potential of inupadenant (EOS100850) when combined with standard chemotherapy drugs, carboplatin and pemetrexed, in treating advanced non-small cell lung cancer in adults. The study is particularly focused on patients for whom previous immunotherapy treatments were not successful.

    The trial has two primary goals. Initially, it seeks to determine the most effective and safest dose of inupadenant when used alongside chemotherapy. Once the optimal dosage is established, the next phase involves comparing the treatment’s effectiveness against a placebo, in combination with the chemotherapy drugs.

    Throughout the study, participants’ health and responses to the treatment are closely monitored.

    BelgiumCzechiaFranceItalyPolandSpain
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Studying samuraciclib and fulvestrant for treating advanced breast cancer

    This clinical trial investigated a new combination therapy for adults with advanced breast cancer that is hormone receptor positive and HER2 negative. Samuraciclib and fulvestrant are used in the treatment, and their effectiveness is compared with fulvestrant alone. The main focus was on the safety and effectiveness of these drugs in the treatment of metastatic or locally advanced breast cancer. Participants will receive combination therapy or fulvestrant alone in a structured setting. The study closely monitors response to treatment, measuring factors such as reduction in tumor size and overall impact on health. The study is crucial to improving treatment for breast cancer and potentially offers new hope for people with advanced stages of the disease.

    Spain
  • Using abemaciclib and darolutamide to fight spreading prostate cancer

    This study is investigating a new combination of two drugs, abemaciclib and darolutamide, to fight advanced prostate cancer that has spread and is not responding after initial treatment. The concept is to determine how safe this combination is and how the patient’s body responds to it. Doctors also want to see how effective these drugs are in controlling cancer. The duration of the study may be up to 32 months. During this period, specialists will carefully monitor possible side effects and the impact of the drugs on the patient’s health. Specialists will try to provide the best possible care to overcome this disease.

    GermanySpain
  • New drug combined with various therapies for solid tumors

    This study evaluates EOS-448, an experimental drug, combined with standard cancer treatments or other investigational therapies in patients with advanced solid tumors. It’s an open-label trial aiming to determine the safety, tolerability, and effectiveness of various drug combinations, including EOS-448. The trial is significant for patients with challenging cancer types, seeking new treatment avenues. Participants will receive EOS-448 with other drugs like pembrolizumab, inupadenant, and dostarlimab, assessing the impact on their cancer.

    BelgiumFranceItalySpainUnited Kingdom
  • Continuation of sodium zirconium cyclosilicate (SZC) therapy in patients with kidney diseases after hospitalization

    This clinical trial investigates the use of sodium zirconium cyclosilicate (SZC) in patients with chronic kidney disease (CKD) treated for hyperkalaemia (high potassium levels) in the hospital. The study compares continuing SZC treatment after discharge with standard care to see if SZC is better at maintaining normal potassium levels and reducing hospital visits. It’s open to adults with CKD and hyperkalaemia. The trial aims to improve post-discharge care and reduce health resource use in these patients.

    BelgiumFranceItalyNetherlandsSpainUnited Kingdom
  • Breast cancer treatment study: camizestrant vs. standard therapy

    This study is looking at a new drug called camizestrant for adults with a certain type of early breast cancer (ER+/HER2-). It compares camizestrant with standard endocrine therapies like tamoxifen and aromatase inhibitors in patients who have already received 2–5 years of endocrine therapy. The study’s focus is on preventing cancer recurrence over 60 months. About 4300 participants are involved, and the trial features an open-label design, meaning everyone knows which treatment they are receiving. The main goal is to check how well the camizestrant works in comparison to standard treatments.

    AustriaBelgiumBulgariaCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Radiation and durvalumab study for early lung cancer patients

    This is a study examining the effectiveness and safety of duvalumab added to high-power radiotherapy to fight stage I or II lung cancer that has not spread to the lymph nodes. Researchers will randomly divide participants into two equal groups. One group will receive Durvalumab, the other – placebo. Both groups will receive the same radiotherapy. The aim is to see if Durvalumab helps people live longer and prevents the cancer from developing again. They also have a separate group who have a specific cancer gene mutation and who will receive osimertinib after radiation therapy. For this group of patients, specialists want to determine whether osimertinib can prevent cancer recurrence for up to four years.

    BelgiumFranceGermanyGreeceItalyNetherlandsPolandSpainUnited Kingdom
  • Study of savolitinib and osimertinib Vs chemotherapy in advancing lung cancer

    This clinical trial will include approximately 324 people with a specific type of advanced lung cancer that has not improved with a specific treatment, osimertinib. People in this study will receive a combination of two drugs, savolitinib and osimertinib, or standard chemotherapy. The aim is to find out which treatment is more effective and safe. A person’s cancer will be monitored to see how it responds to treatment. If the cancer gets worse or the side effects become too much to bear, the person may stop participating in the study. The study will measure responses such as the number of people who see improvement in their cancer treatment, the time it takes for symptoms to get worse and the presence of drugs in the body.

    AustriaBelgiumBulgariaFranceGermanyGreeceItalyPolandSpainUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain

See more clinical trials in other cities in Spain:

.